DE69532625D1 - NK-1 Rezeptor-Antagonisten zur Behandlung von neuronalen Schäden und Schlaganfällen - Google Patents
NK-1 Rezeptor-Antagonisten zur Behandlung von neuronalen Schäden und SchlaganfällenInfo
- Publication number
- DE69532625D1 DE69532625D1 DE69532625T DE69532625T DE69532625D1 DE 69532625 D1 DE69532625 D1 DE 69532625D1 DE 69532625 T DE69532625 T DE 69532625T DE 69532625 T DE69532625 T DE 69532625T DE 69532625 D1 DE69532625 D1 DE 69532625D1
- Authority
- DE
- Germany
- Prior art keywords
- stroke
- derivatives
- neuronal damage
- receptor antagonists
- epilepsy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35470294A | 1994-12-12 | 1994-12-12 | |
US354702 | 1994-12-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69532625D1 true DE69532625D1 (de) | 2004-04-08 |
DE69532625T2 DE69532625T2 (de) | 2005-02-03 |
Family
ID=23394558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69532625T Revoked DE69532625T2 (de) | 1994-12-12 | 1995-12-07 | NK-1 Rezeptor-Antagonisten zur Behandlung von neuronalen Schäden und Schlaganfällen |
Country Status (16)
Country | Link |
---|---|
US (1) | US6376507B1 (de) |
EP (1) | EP0721778B1 (de) |
JP (1) | JPH08239323A (de) |
KR (1) | KR100195651B1 (de) |
CN (1) | CN1132072A (de) |
AT (1) | ATE260656T1 (de) |
AU (1) | AU719159B2 (de) |
CA (1) | CA2164804C (de) |
DE (1) | DE69532625T2 (de) |
DK (1) | DK0721778T3 (de) |
ES (1) | ES2217274T3 (de) |
IL (1) | IL116249A (de) |
MY (1) | MY138631A (de) |
NZ (1) | NZ280627A (de) |
PT (1) | PT721778E (de) |
ZA (1) | ZA9510483B (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
CO5011067A1 (es) * | 1997-11-03 | 2001-02-28 | Novartis Ag | Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen |
AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
JP2008500324A (ja) * | 2004-05-25 | 2008-01-10 | ファイザー・プロダクツ・インク | 3−アミノ−2−フェニルピロリジン誘導体 |
GB0701365D0 (en) * | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
JP6334098B2 (ja) * | 2013-06-24 | 2018-05-30 | セイコーインスツル株式会社 | 表示機構、時計用ムーブメントおよび時計 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
DE69105131T2 (de) * | 1990-06-01 | 1995-03-23 | Pfizer | 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen. |
CA2086434C (en) * | 1990-07-23 | 1998-09-22 | John A. Lowe, Iii | Quinuclidine derivatives |
JPH0733385B2 (ja) * | 1991-01-10 | 1995-04-12 | フアイザー・インコーポレイテツド | 物質pの拮抗薬としてのn−アルキルキヌクリジニウム塩 |
DE69200921T2 (de) * | 1991-03-01 | 1995-05-04 | Pfizer | 1-azabicyclo[3.2.2]nonan-3-aminderivate. |
ES2084361T3 (es) * | 1991-05-31 | 1996-05-01 | Pfizer | Derivados de quinuclidina. |
CZ59394A3 (en) * | 1991-09-26 | 1994-11-16 | Pfizer | Condensed tricyclic heterocycles containing nitrogen as antagonists of p substance receptor, process of their preparation, intermediates, pharmaceutical preparations in which they are comprised and use |
JP2656702B2 (ja) * | 1992-03-23 | 1997-09-24 | ファイザー製薬株式会社 | ペプチド性キヌクリジン |
US5721255A (en) * | 1992-08-19 | 1998-02-24 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
US5703065A (en) * | 1993-09-17 | 1997-12-30 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benyzlaminomethyl piperidines and related compounds |
DE69418046T2 (de) * | 1994-11-16 | 1999-12-30 | Bird Sa | Modularfahrradrahmen mit Vibrationsdämpfer |
IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
-
1995
- 1995-12-04 IL IL11624995A patent/IL116249A/xx not_active IP Right Cessation
- 1995-12-05 MY MYPI95003742A patent/MY138631A/en unknown
- 1995-12-07 PT PT95308876T patent/PT721778E/pt unknown
- 1995-12-07 EP EP95308876A patent/EP0721778B1/de not_active Revoked
- 1995-12-07 DE DE69532625T patent/DE69532625T2/de not_active Revoked
- 1995-12-07 ES ES95308876T patent/ES2217274T3/es not_active Expired - Lifetime
- 1995-12-07 DK DK95308876T patent/DK0721778T3/da active
- 1995-12-07 AT AT95308876T patent/ATE260656T1/de not_active IP Right Cessation
- 1995-12-08 NZ NZ280627A patent/NZ280627A/en unknown
- 1995-12-08 AU AU40304/95A patent/AU719159B2/en not_active Ceased
- 1995-12-08 CA CA002164804A patent/CA2164804C/en not_active Expired - Fee Related
- 1995-12-08 CN CN95120596A patent/CN1132072A/zh active Pending
- 1995-12-09 KR KR1019950048062A patent/KR100195651B1/ko not_active IP Right Cessation
- 1995-12-11 ZA ZA9510483A patent/ZA9510483B/xx unknown
- 1995-12-12 JP JP7323355A patent/JPH08239323A/ja active Pending
-
1998
- 1998-06-18 US US09/099,289 patent/US6376507B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0721778A3 (de) | 1999-11-10 |
CA2164804A1 (en) | 1996-06-13 |
EP0721778A2 (de) | 1996-07-17 |
US6376507B1 (en) | 2002-04-23 |
JPH08239323A (ja) | 1996-09-17 |
ZA9510483B (en) | 1997-06-09 |
AU4030495A (en) | 1996-06-20 |
EP0721778B1 (de) | 2004-03-03 |
ATE260656T1 (de) | 2004-03-15 |
KR960021025A (ko) | 1996-07-18 |
DK0721778T3 (da) | 2004-07-12 |
IL116249A0 (en) | 1996-03-31 |
AU719159B2 (en) | 2000-05-04 |
KR100195651B1 (ko) | 1999-06-15 |
ES2217274T3 (es) | 2004-11-01 |
DE69532625T2 (de) | 2005-02-03 |
MY138631A (en) | 2009-07-31 |
IL116249A (en) | 2003-07-06 |
NZ280627A (en) | 2000-06-23 |
CN1132072A (zh) | 1996-10-02 |
PT721778E (pt) | 2004-07-30 |
CA2164804C (en) | 1999-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60022050T2 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
DE69434431D1 (de) | Methoden zur behandlung von muskelerkrankungen und muskelstörungen | |
EP0722737A4 (de) | Arznei gegen die störung des cranialen nervan | |
EP0686629A3 (de) | Cyclohexyl-Antagonisten von Tachykininrezeptoren | |
DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
DK0831799T3 (da) | Forbindelser, der er aktive ved et nyt sted på receptor-stimulerede calsiumkanaler, og som kan anvendes til behandling af neurologiske sygdomme | |
BR0200283A (pt) | Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios | |
DE69434313D1 (de) | Superoxiddismutase memetika | |
PL369535A1 (en) | Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury | |
DE69532625D1 (de) | NK-1 Rezeptor-Antagonisten zur Behandlung von neuronalen Schäden und Schlaganfällen | |
ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
DE69838882D1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
DE69432626D1 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen | |
DE69431199D1 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE69621786T2 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
ATE256126T1 (de) | 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen | |
DE69626916T2 (de) | Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten | |
DE69833727D1 (de) | Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C | |
MX9703483A (es) | Antagonistas del receptor de nk-1 para el tratamiento de trastornos oculares. | |
WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's | |
DE69307702T2 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
DE69731620D1 (de) | Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten | |
ATE201993T1 (de) | Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie | |
DE69911436D1 (de) | Die verwendung von r (+)- g(a)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol zur behandlung von obstruktive schlafapnoe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8331 | Complete revocation |